At 14:30 CET/08:30 Eastern Time, Algeta's executive management team will also host an international conference call.

To participate in the conference call, please dial the appropriate number below five minutes prior to the call:

US: +1 877 423 0830
UK: +44 20 7153 9154
Norway: +47 21 06 61 13
Sweden: +46 8-506 443 86
Denmark: +45 32 71 42 62
Switzerland: +41 44 580 65 22

Participant pin code: 873878#

To access the replay, please dial:

US: +1 877 679 2989
UK: +44 203 364 5200
Norway: +47 23 50 02 03
Sweden: +46 8-505 564 73

Conference reference: 348995#

A replay of the conference call will also be available at www.algeta.com.

The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.

###

For further information, please contact:

Mike Booth +1 646 410 1884
Communications & Corporate Affairs ir@algeta.com
Media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk
Knut Ekern +47 22 04 82 00
Gambit Hill & Knowlton knut.ekern@hkstrategies.com
Kari Watson +1 781 235 3060
MacDougall Biomedical Communications kwatson@macbiocom.com
Investor enquiries:
Tricia Truehart +1 646 378 2953
The Trout Group ttruehart@troutgroup.com

About Algeta

Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

distributed by